Abstract: The present invention provides a human lung growth factor variant (LGFV) and polynucleotides which identify and encode LGFV. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding LGFV and a method for producing LGFV. The invention also provides for agonists, antibodies, or antagonists specifically binding LGFV, and their use, in the prevention and treatment of diseases associated with expression of LGFV. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding LGFV for the treatment of diseases associated with the expression of LGFV. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding LGFV.
Type:
Grant
Filed:
December 5, 1996
Date of Patent:
October 26, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Olga Bandman, Surya K. Goli, Lynn E. Murry
Abstract: The invention provides a human microfibril-associated glycoprotein 4 splice variant (MAG4V) and polynucleotides which identify and encode MAG4V. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of MAG4V.
Type:
Grant
Filed:
January 20, 1998
Date of Patent:
October 26, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Y. Tom Tang, Neil C. Corley, Purvi Shah
Abstract: The invention provides a human hydroxypyruvate reductase (HHPR) and polynucleotides which identify and encode HHPR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HHPR.
Type:
Grant
Filed:
October 22, 1997
Date of Patent:
October 26, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Preeti Lal, Purvi Shah
Abstract: The invention provides a human multiple endocrine neoplasia type 1 protein (MEND1) and polynucleotides which identify and encode MEND1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of MEND1.
Type:
Grant
Filed:
May 29, 1997
Date of Patent:
October 26, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Janice Au-Young, Peter A. Covitz, Y. Tom Tang, Lynn E. Murry
Abstract: The invention provides a human cornichon protein (CORN) and polynucleotides which identify and encode CORN. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of CORN.
Type:
Grant
Filed:
October 14, 1997
Date of Patent:
October 19, 1999
Assignee:
Incyte Pharmaceticals, Inc.
Inventors:
Jennifer L. Hillman, Neil C. Corley, Purvi Shah
Abstract: The present invention provides a new human GPI2 homolog (GPI-2h) and polynucleotides which identify and encode GPI-2h. The invention also provides expression vectors, host cells, antibodies, and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of GPI-2h, as well as diagnostic assays.
Type:
Grant
Filed:
May 22, 1997
Date of Patent:
October 19, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Olga Bandman, Neil C. Corley, Purvi Shah
Abstract: The present invention provides a polynucleotide (mctl) which identifies and encodes a novel human C-type lectin (MCTL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MCTL. The invention also provides for the use of substantially purified MCTL and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of MCTL. Additionally, the invention provides for the use of antisense molecules to mctl in pharmaceutical compositions for treatment of diseases associated with the expression of MCTL. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of mctl. The present invention also relates to anti-MCTL antibodies which specifically bind to MCTL.
Type:
Grant
Filed:
July 10, 1998
Date of Patent:
October 19, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Janice Au-Young, Benjamin Graeme Cocks, Surya K. Goli, Jennifer L. Hillman
Abstract: The invention provides a human ubiquitin-like conjugating protein (UBCLE) and polynucleotides which identify and encode UBCLE. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of UBCLE.
Type:
Grant
Filed:
December 12, 1997
Date of Patent:
October 19, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Purvi Shah, Neil C. Corley
Abstract: The invention provides a human glutaredoxin .beta. (GRX.beta.) and polynucleotides which identify and encode GRX.beta.. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of GRX.beta..
Type:
Grant
Filed:
August 14, 1997
Date of Patent:
October 19, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Neil C. Corley, Purvi Shah
Abstract: The present invention provides a human serine protease precursor (HSPP) and polynucleotides which encode HSPP. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of HSPP.
Type:
Grant
Filed:
December 15, 1998
Date of Patent:
October 12, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Neil C. Corley, Purvi Shah
Abstract: The present invention provides two novel human cathepsin proteins (HCPs) and polynucleotides encoding HCPs. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HCPs. The invention also provides for the production and use of antibodies to HCPs in pharmaceutical compositions for the treatment of disease processes that include cancers, inflammation, metastasis and peptide and proenzyme processing. In addition, the invention provides for the production and use of inhibitors of HSPs in pharmaceutical compositions for the treatment of diseases. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HCPs. The invention also provides for the use of antisense molecules in pharmaceutical compositions as therapeutics in cancers, inflammation, metastasis and peptide and proenzyme processing.
Abstract: The present invention provides a human regulator of gene transcription (HRGT) and polynucleotides which encode HRGT. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of HRGT.
Type:
Grant
Filed:
April 24, 1998
Date of Patent:
October 12, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Surya K. Goli, David G. Streeter
Abstract: The present invention provides a human growth factor receptor binding protein (HSTPK) and polynucleotides which encode HSTPK. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for producing HSTPK and for treating disorders associated with expression of HSTPK.
Type:
Grant
Filed:
March 14, 1997
Date of Patent:
October 12, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Olga Bandman, Karl J. Guegler, Preeti Lal
Abstract: The invention provides a human lysophospholipase (NHLP) and polynucleotides which identify and encode NHLP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of NHLP.
Type:
Grant
Filed:
February 12, 1998
Date of Patent:
October 12, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Purvi Shah, Lynn E. Murry
Abstract: The invention provides human succinyl-CoA synthetase holoenzyme (SCSH) and polynucleotides which identify and encode SCSH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of SCSH.
Type:
Grant
Filed:
June 18, 1998
Date of Patent:
October 12, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Olga Bandman, Preeti Lal, Neil C. Corley, Chandra Patterson
Abstract: The invention provides a human maternally transcribed protein (HMTP) and polynucleotides which identify and encode HMTP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HMTP.
Type:
Grant
Filed:
October 3, 1997
Date of Patent:
October 12, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Preeti Lal, Neil C. Corley
Abstract: The invention provides a human importin alpha homolog (IMPAH) and polynucleotides which identify and encode IMPAH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of IMPAH.
Type:
Grant
Filed:
September 18, 1997
Date of Patent:
October 12, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Olga Bandman, Karl J. Guegler, Neil C. Corley, Purvi Shah
Abstract: The invention provides a new human heat shock 27 like protein, (HSP27P) and polynucleotides which identify and encode HSP27P. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HSP27P.
Type:
Grant
Filed:
July 25, 1997
Date of Patent:
October 5, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Preeti Lal, Neil C. Corley, Purvi Shah
Abstract: The invention provides human membrane recycling proteins (HMRP) and polynucleotides which identify and encode HMRP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HMRP.
Abstract: The present invention provides a human RNA bind-protein (HRNABP) and polynucleotides which identify and encode HRNABP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HRNABP and a method for producing HRNABP. The invention also provides for antagonists or antibodies specifically binding HRNABP, and their use, in the prevention and treatment of diseases associated with expression of HRNABP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HRNABP for the treatment of diseases associated with the expression of HRNABP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HRNABP.